Analysts expect bluebird bio Inc (NASDAQ:BLUE) to report $101.74 million in sales for the current fiscal quarter, according to Zacks Investment Research. Seven analysts have issued estimates for bluebird bio’s earnings, with estimates ranging from $14.00 million to $208.50 million. bluebird bio posted sales of $13.30 million during the same quarter last year, which would indicate a positive year-over-year growth rate of 665%. The business is scheduled to report its next quarterly earnings results on Thursday, August 6th.
On average, analysts expect that bluebird bio will report full year sales of $211.16 million for the current year, with estimates ranging from $80.00 million to $443.00 million. For the next year, analysts anticipate that the company will post sales of $146.98 million, with estimates ranging from $79.90 million to $256.05 million. Zacks’ sales averages are an average based on a survey of analysts that follow bluebird bio.
bluebird bio (NASDAQ:BLUE) last issued its quarterly earnings data on Monday, May 11th. The biotechnology company reported ($3.64) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($4.05) by $0.41. The business had revenue of $21.90 million during the quarter, compared to analyst estimates of $8.00 million. bluebird bio had a negative net margin of 1,531.04% and a negative return on equity of 60.05%. The firm’s quarterly revenue was up 75.2% on a year-over-year basis. During the same quarter last year, the business earned ($2.99) EPS.
A number of analysts have weighed in on the stock. BMO Capital Markets increased their target price on shares of bluebird bio from $107.00 to $112.00 and gave the company an “outperform” rating in a research report on Tuesday, May 12th. Zacks Investment Research raised shares of bluebird bio from a “hold” rating to a “buy” rating and set a $65.00 target price for the company in a research report on Tuesday, April 28th. Barclays reissued a “buy” rating on shares of bluebird bio in a research report on Wednesday, May 13th. BidaskClub downgraded shares of bluebird bio from a “hold” rating to a “sell” rating in a research report on Thursday, June 18th. Finally, William Blair reissued a “hold” rating on shares of bluebird bio in a research report on Friday, March 27th. One research analyst has rated the stock with a sell rating, four have given a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $106.14.
In related news, insider Joanne Smith-Farrell sold 583 shares of the stock in a transaction on Monday, April 6th. The stock was sold at an average price of $43.73, for a total value of $25,494.59. Following the transaction, the insider now directly owns 21,393 shares in the company, valued at approximately $935,515.89. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Nick Leschly sold 444 shares of the stock in a transaction on Tuesday, June 2nd. The stock was sold at an average price of $64.04, for a total value of $28,433.76. Following the completion of the transaction, the chief executive officer now owns 100,688 shares in the company, valued at $6,448,059.52. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 1,218 shares of company stock valued at $66,343. Insiders own 3.00% of the company’s stock.
Several institutional investors and hedge funds have recently modified their holdings of BLUE. Clearbridge Investments LLC lifted its holdings in shares of bluebird bio by 36.7% in the 1st quarter. Clearbridge Investments LLC now owns 908 shares of the biotechnology company’s stock worth $42,000 after purchasing an additional 244 shares in the last quarter. Tower Research Capital LLC TRC purchased a new stake in shares of bluebird bio in the fourth quarter worth $47,000. Harbor Investment Advisory LLC grew its stake in shares of bluebird bio by 69.7% in the first quarter. Harbor Investment Advisory LLC now owns 1,188 shares of the biotechnology company’s stock worth $55,000 after acquiring an additional 488 shares during the last quarter. NuWave Investment Management LLC grew its stake in shares of bluebird bio by 174.6% in the first quarter. NuWave Investment Management LLC now owns 1,538 shares of the biotechnology company’s stock worth $71,000 after acquiring an additional 978 shares during the last quarter. Finally, Nisa Investment Advisors LLC grew its stake in shares of bluebird bio by 63.2% in the first quarter. Nisa Investment Advisors LLC now owns 1,860 shares of the biotechnology company’s stock worth $85,000 after acquiring an additional 720 shares during the last quarter.
NASDAQ BLUE traded up $0.39 during trading hours on Friday, reaching $60.48. The company’s stock had a trading volume of 13,039 shares, compared to its average volume of 1,196,580. The firm has a fifty day simple moving average of $63.18 and a 200-day simple moving average of $69.81. The stock has a market cap of $3.34 billion, a P/E ratio of -4.03 and a beta of 2.39. bluebird bio has a 52 week low of $38.95 and a 52 week high of $143.98. The company has a debt-to-equity ratio of 0.16, a current ratio of 5.25 and a quick ratio of 5.25.
About bluebird bio
bluebird bio, Inc, a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates in severe genetic diseases include LentiGlobin, which is in various clinical studies for the treatment of transfusion-dependent ß-thalassemia and severe sickle cell disease; and Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder.
Featured Article: How do taxes affect a CDs total return?
Get a free copy of the Zacks research report on bluebird bio (BLUE)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.